Iterum Therapeutics resubmits new drug application to U.S. FDA for oral sulopenem

seekingalpha04-29

Iterum Therapeutics plc (NASDAQ:ITRM) announced that it has resubmitted its New Drug Application to the U.S. FDA for sulopenem etzadroxil/probenecid (oral sulopenem) for the treatment of uncomplicated...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2431529028?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-29 20:47","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2431529028","market":"nz","top_or_hot":-1,"title":"Iterum Therapeutics resubmits new drug application to U.S. FDA for oral sulopenem","media":"seekingalpha","content":"<div>\n<p>Iterum Therapeutics plc (NASDAQ:ITRM) announced that it has resubmitted its New Drug Application to the U.S. FDA for sulopenem etzadroxil/probenecid (oral sulopenem) for the treatment of uncomplicated...</p>\n\n<a href=\"https://seekingalpha.com/news/4095445-iterum-therapeutics-resubmits-new-drug-application-to-us-fda-for-oral-sulopenem\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Iterum Therapeutics resubmits new drug application to U.S. FDA for oral sulopenem</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIterum Therapeutics resubmits new drug application to U.S. FDA for oral sulopenem\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-29 20:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4095445-iterum-therapeutics-resubmits-new-drug-application-to-us-fda-for-oral-sulopenem><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Iterum Therapeutics plc (NASDAQ:ITRM) announced that it has resubmitted its New Drug Application to the U.S. FDA for sulopenem etzadroxil/probenecid (oral sulopenem) for the treatment of uncomplicated...</p>\n\n<a href=\"https://seekingalpha.com/news/4095445-iterum-therapeutics-resubmits-new-drug-application-to-us-fda-for-oral-sulopenem\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ITRM","symbol_name":"Iterum Therapeutics Plc","start_time":0,"source_url":"https://seekingalpha.com/news/4095445-iterum-therapeutics-resubmits-new-drug-application-to-us-fda-for-oral-sulopenem","article_id":"2431529028","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2431529028","pubTimestamp":1714394821,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Iterum Therapeutics plc (NASDAQ:ITRM) announced that it has resubmitted its New Drug Application to the U.S. FDA for sulopenem etzadroxil/probenecid (oral sulopenem) for the treatment of uncomplicated","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"ITRM":"Iterum Therapeutics Plc","BK4007":"制药","BK4139":"生物科技","LENZ":"Therapeutics"},"translate_title":"Iterum Therapeutics向美国FDA重新提交口服苏洛培南新药申请","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ITRM":1,"LENZ":1},"content_text":"Iterum Therapeutics plc (NASDAQ:ITRM) announced that it has resubmitted its New Drug Application to the U.S. FDA for sulopenem etzadroxil/probenecid (oral sulopenem) for the treatment of uncomplicated urinary tract infections in adult women. The NDA resubmission includes data from the REASSURE, SURE (Sulopenem for Resistant Enterobacteriaceae) 1, SURE 2 and SURE 3 phase 3 clinical trials, in which oral sulopenem was well tolerated with no safety issues identified.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2431529028"}